HB639, titled the “Doctor Knows Best Act of 2025,” would bar group health plans, health insurance issuers, and certain federal health care programs from using prior authorization, utilization management tools, or medical necessity reviews for covered items and services. In practical terms, the bill would prohibit insurers and program administrators from requiring advance approval before care is provided, and it would also ban related controls such as step therapy and fail-first protocols.
For private coverage, the bill would amend the Public Health Service Act to prevent group and individual health plans from imposing these restrictions. For federal health programs, including programs defined under the Social Security Act and the Federal Employees Health Benefits Program, the prohibition would begin on January 1, 2026. The private-insurance amendment would apply to plan years beginning on or after January 1, 2026.
Impact
The bill would significantly limit insurer and government program oversight of medical services by removing prior authorization and related utilization management requirements from covered benefits. It would amend federal health insurance law and affect group health plans, individual market issuers, and federal health care programs, shifting decision-making authority toward treating clinicians and patients. If enacted, it would likely reduce administrative barriers to care but also constrain a major cost-control and coverage-management tool used by insurers and public programs.
Sentiment
The bill’s framing and title suggest a strongly pro-patient, pro-physician policy approach, and the text reflects a clear intent to reduce insurer interference in treatment decisions. However, the provided record contains no committee transcript or vote data, so there is no direct evidence of debate, amendments, or bipartisan support/opposition in the available materials. Based on the bill’s substance alone, it appears designed to appeal to critics of insurance delays and denials.
Contention
The main point of contention would likely be the tradeoff between patient access and cost/utilization control. Supporters would favor eliminating delays, denials, and administrative burdens associated with prior authorization, step therapy, and medical necessity reviews. Opponents would likely argue that these tools help prevent unnecessary or low-value care, manage spending, and maintain program integrity. No specific member positions or committee objections are available in the provided context.